ReviewJournal of neuro-oncology1999
Neurologic sequelae of treatment of primary CNS lymphomas.
Review in Journal of neuro-oncology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 42 citations in OpenAlex.
- [White matter alterations after chemotherapy and radiation].Der Radiologe · 2018Review
- Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Review
- Computer-based assessment of cognitive functions in brain tumor patients.Journal of neuro-oncology · 2010Article
- Radiation dose-volume effects in the brain.International journal of radiation oncology, biology, physics · 2010Review
- [Acute central nervous symptoms in oncologic patients].Der Internist · 2005Review
- Primary Central Nervous System Lymphoma.Current treatment options in neurology · 2003Article
- Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.Journal of neuro-oncology · 2003Article
- Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?Proceedings of the National Academy of Sciences of the United States of America · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel efficient and aggressive treatment protocols for primary CNS lymphomas have resulted in an increasing number of long term survivors. Follow up data show that in a substantial fraction of these patients, treatment benefits are overshadowed by neurotoxic sequelae. Neurotoxicity especially affects the older age group, presenting as cognitive dysfunction, ataxia or dementia as a consequence of leukoencephalopathy and brain atrophy. The combination of radiotherapy and chemotherapy seems to be particularly hazardous, though data are too sparse to draw any definite conclusions yet. Long term follow up of patients included in clinical studies therefore should not only evaluate survival or time to tumour progression, but also serial neuropsychometric evaluation and quality of life assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.